NASDAQ:BEAT - BioTelemetry Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $57.25 +1.05 (+1.87 %) (As of 08/21/2018 04:00 PM ET)Previous Close$56.20Today's Range$56.30 - $57.4952-Week Range$23.30 - $58.50Volume219,700 shsAverage Volume380,589 shsMarket Capitalization$1.87 billionP/E Ratio59.02Dividend YieldN/ABeta1.3 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioTelemetry, Inc., a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry service; and event monitoring services to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and pacemaker and international normalized ratio monitoring services to cardiologists and electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, including cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. This segment's centralized services comprise ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices that include event monitors, digital Holter monitors, and mobile cardiac telemetry monitors, as well as a wireless BGM system. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania. Receive BEAT News and Ratings via Email Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Specialty outpatient clinics, not elsewhere classified Sub-IndustryN/A SectorMedical SymbolNASDAQ:BEAT CUSIPN/A Webwww.gobio.com Phone610-729-7000 Debt Debt-to-Equity Ratio0.72 Current Ratio2.29 Quick Ratio2.12 Price-To-Earnings Trailing P/E Ratio59.02 Forward P/E Ratio38.95 P/E Growth3.88 Sales & Book Value Annual Sales$286.78 million Price / Sales6.55 Cash Flow$1.8807 per share Price / Cash30.44 Book Value$7.70 per share Price / Book7.44 Profitability EPS (Most Recent Fiscal Year)$0.97 Net Income$-15,950,000.00 Net Margins-0.39% Return on Equity18.02% Return on Assets8.90% Miscellaneous Employees1,600 Outstanding Shares32,790,000Market Cap$1.87 billion BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions What is BioTelemetry's stock symbol? BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT." How were BioTelemetry's earnings last quarter? BioTelemetry Inc (NASDAQ:BEAT) posted its quarterly earnings data on Wednesday, July, 25th. The medical research company reported $0.46 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.31 by $0.15. The medical research company earned $101.36 million during the quarter, compared to analyst estimates of $95.87 million. BioTelemetry had a negative net margin of 0.39% and a positive return on equity of 18.02%. The business's revenue for the quarter was up 74.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.23 earnings per share. View BioTelemetry's Earnings History. When is BioTelemetry's next earnings date? BioTelemetry is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for BioTelemetry. What price target have analysts set for BEAT? 6 brokerages have issued twelve-month price objectives for BioTelemetry's shares. Their predictions range from $37.00 to $90.00. On average, they expect BioTelemetry's stock price to reach $52.60 in the next year. This suggests that the stock has a possible downside of 8.1%. View Analyst Price Targets for BioTelemetry. What is the consensus analysts' recommendation for BioTelemetry? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTelemetry. Who are some of BioTelemetry's key competitors? Some companies that are related to BioTelemetry include Canopy Growth (CGC), SAGE Therapeutics (SAGE), NMC Health (NMC), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), BIO-TECHNE (TECH), GN STORE NORD A/ADR (GNNDY), PRA Health Sciences (PRAH), Amneal Pharmaceuticals (AMRX), Canopy Growth (WEED), Hill-Rom (HRC), athenahealth (ATHN), ICU Medical (ICUI), LivaNova (LIVN) and EXACT Sciences (EXAS). Who are BioTelemetry's key executives? BioTelemetry's management team includes the folowing people: Mr. Joseph H. Capper, CEO, Pres & Director (Age 54)Ms. Heather C. Getz, Exec. VP & CFO (Age 43)Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 49)Mr. Fred Broadway III, Pres of BioTel Heart (Age 48)Dr. Peter R. Kowey, Medical Director and Chairman of Medical Advisory Board Has BioTelemetry been receiving favorable news coverage? Press coverage about BEAT stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioTelemetry earned a media and rumor sentiment score of 0.06 on Accern's scale. They also gave media headlines about the medical research company an impact score of 46.22 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for BioTelemetry. Who are BioTelemetry's major shareholders? BioTelemetry's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.02%), Dimensional Fund Advisors LP (4.21%), Macquarie Group Ltd. (3.90%), Hood River Capital Management LLC (3.38%), Bank of New York Mellon Corp (3.05%) and Glenmede Trust Co. NA (2.94%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry. Which institutional investors are selling BioTelemetry stock? BEAT stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Thompson Siegel & Walmsley LLC, Russell Investments Group Ltd., Hodges Capital Management Inc., Cannell Capital LLC, Summit Creek Advisors LLC, Glenmede Trust Co. NA and Hood River Capital Management LLC. Company insiders that have sold BioTelemetry company stock in the last year include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Insider Buying and Selling for BioTelemetry. Which institutional investors are buying BioTelemetry stock? BEAT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Castleark Management LLC, Millennium Management LLC, EAM Investors LLC, First Trust Advisors LP, Sei Investments Co., Cornerstone Wealth Management LLC and EAM Global Investors LLC. View Insider Buying and Selling for BioTelemetry. How do I buy shares of BioTelemetry? Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioTelemetry's stock price today? One share of BEAT stock can currently be purchased for approximately $57.25. How big of a company is BioTelemetry? BioTelemetry has a market capitalization of $1.87 billion and generates $286.78 million in revenue each year. The medical research company earns $-15,950,000.00 in net income (profit) each year or $0.97 on an earnings per share basis. BioTelemetry employs 1,600 workers across the globe. How can I contact BioTelemetry? BioTelemetry's mailing address is 1000 Cedar Hollow Road, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected] MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 254 (Vote Outperform)Underperform Votes: 220 (Vote Underperform)Total Votes: 474MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/21/2018 by MarketBeat.com StaffFeatured Article: What do investors mean by earnings per share?